CD274 and neoplasm: Combining Atezolizumab (anti-PD-L1) with bevacizumab (anti-vascular endothelial growth factor [VEGF]) increases the efficacy of Atezolizumab by reversing VEGF-mediated immunosuppression and promoting T-cell infiltration into the tumor [11,12].